Background {#Sec1}
==========

Lung cancer is the leading cause of deaths worldwide, including in Taiwan. The 5-year overall survival (OS) rate of advanced-stage lung cancer is less than 20% \[[@CR1]\]. Tyrosine kinase inhibitors (TKIs, erlotinib or gefitinib) have been prescribed in lung adenocarcinoma patients who have epidermal growth factor receptor (EGFR) mutations and have markedly improved the survival outcome, but patients still eventually develop TKI resistance \[[@CR2], [@CR3]\]. Thus, a more comprehensive understanding of lung carcinogenesis is necessary to develop more effective therapies.

Overexpression of EGFR is implicated in the pathogenesis of many human malignancies, including lung cancer \[[@CR4]\]. EGFR overexpression has been reported to be strongly associated with cancer progression and to predict shorter survival in surgically resected non-small cell lung cancer (NSCLC) \[[@CR5], [@CR6]\]. Nevertheless, high EGFR expression may predict the response to gefitinib in lung adenocarcinoma with a high survival and provide survival benefits when gefitinib is used in combination with cetuximab in advanced NSCLC with wildtype EGFR status \[[@CR7]--[@CR9]\]. Therefore, a more detailed understanding of EGFR biology in lung carcinomas is required.

The localization of nuclear EGFR, which has been detected in various cancers in the last decade, functions as a transcription factor for cell proliferation, angiogenesis and resistance to standard therapy \[[@CR10]\]. Nuclear EGFR expression has been reported to be related to disease progression and poor survival time in breast, ovary and oropharynx cancers as well as in early stage NSCLC \[[@CR11]--[@CR14]\]. However, few studies investigate the relationship of between EGFR proteins and EGFR mutations \[[@CR15], [@CR16]\].

Since the clinical correlation of differentially located EGFR proteins in lung cancer has not been completely evaluated; therefore, we intended to investigate the relevance of differentially located EGFR expression in lung adenocarcinoma. This study retrospectively graded differentially located EGFR expressions in 161 lung adenocarcinoma specimens by using immunohistochemistry (IHC) and determined the association with demographic characteristics, stages, EGFR mutation status, and survival time.

Methods {#Sec2}
=======

Patients and tumor specimens {#Sec3}
----------------------------

Formalin-fixed paraffin-embedded tumors from 161 patients with lung adenocarcinoma diagnosed based on 2015 WHO classifications \[[@CR17]\], who had undergone computed tomography-guided needle biopsies or wedge resections were collected from Taipei Medical University-Wan Fang Hospital between 2008 and 2014. The clinical parameters and follow-up data were obtained by reviewing medical records. The patients were followed until December 2016; the median follow-up period was 13.1 months (0.07--132.03). All survivors were followed for at least 12 months. This study was approved by the Joint Institutional Review Board of Taipei Medical University.

Immunohistochemistry {#Sec4}
--------------------

Four-micrometer sections of paraffin-embedded blocks were deparaffinized in xylene substitute, rehydrated with alcohol, and subjected to antigen retrieval. To detect EGFR proteins in the different cellular compartments of cancer cells, we used two types of primary EGFR antibodies to recognize EGFR proteins by the specific terminus. The mouse anti-EGFr antibody (clone 31G7, Invitrogen, Breda, the Netherlands) is raised against the NH2 terminus and recognizes membranous EGFR (**m**EGFR) and cytoplasmic EGFR \[[@CR18]\]; the NCL-EGFR-384 antibody (clone EGFR.25, Novocastra, Newcastle, upon Tyne, UK) is raised against the COOH terminus and recognizes both **m**EGFR and nuclear EGFR (**n**EGFR) \[[@CR11], [@CR19]\]. Appropriate antigen retrieval protocols were used according to the specific primary antibodies. For **m**EGFR protein detection, we used the enzyme digestion method with pepsin (Digest-All™ 1, Thermo Fisher Scientific) for 10 min at 37 °C and for **n**EGFR protein detection, we used the double-antigen retrieval method, heat-induced epitope retrieval (boiling citrate buffer for 5 min) plus enzyme digestion with 0.025% trypsin **(**T4799, [Sigma Aldrich](http://www.sigmaaldrich.com/technical-documents/articles/biology/trypsin.html)) for 8 min at room temperature (RT). Slides were incubated at RT with the mouse anti-EGFr antibody overnight and at 4 °C with the NCL-EGFR-384 antibody overnight. The labeled streptavidin biotin method with horse radish peroxidase was used to achieve signal amplifications. Immunoreactions were visualized using 3.3′-diamino-benzidine-tetrahydrochloryte, then counterstained with hematoxylin.

IHC interpretation {#Sec5}
------------------

**m**EGFR and **n**EGFR expression was interpreted as high and low expression from IHC images. We graded complete membranous staining with strong intensity in more than 10% of cancer cells as high **m**EGFR expression and others (incomplete membranous, weak or less than 10% of cancer cells staining) as low **m**EGFR expression. Nuclear staining with strong intensity in more than 10% of cancer cells was graded as high **n**EGFR expression and others were as low **n**EGFR expression. Lung squamous cell carcinoma tissue, known to have **m**EGFR overexpression, served as the positive control for **m**EGFR staining and hepatocellular carcinoma tissue served as the positive control for **n**EGFR staining. The negative controls of **m**EGFR and **n**EGFR comprised slides with the mouse IGG1 isotype antibody. The immunostain grading was done by two designated pathologists (C-L. F. and S-E. L.) with total agreement blindly. Figure [1](#Fig1){ref-type="fig"} shows representative images for **m**EGFR and **n**EGFR expression.Fig. 1Immunostaining for **m**EGFR and **n**EGFR proteins in lung adenocarcinoma tissues. **a** high **m**EGFR expression; **b** low **m**EGFR expression; **c** positive **m**EGFR control (lung squamous cell carcinoma); **d** high **n**EGFR expression; **e** low **n**EGFR expression; **f** positive **n**EGFR control (hepatocellular carcinoma). Original magnification × 400

Statistical analyses {#Sec6}
--------------------

The Pearson chi-squared test was performed to analyze the associations between differentially located EGFR proteins and clinical characteristics. The Kaplan-Meier estimate by using the log-rank test was employed to evaluate the survival distributions for differentially located EGFR proteins. OS was defined as the time between the date of diagnosis and that of death from any causes or the date of censorship (date of final follow-up). Progression-free survival (PFS) was defined as the time between the date of treatment initiation to that of tumor progression, death from any causes, or censorship. To evaluate the mortality risk, the hazard ratio (HR) and corresponding confidence interval (CI) were estimated using Cox proportional hazards models to identify potential prognostic factors. All statistical analyses were conducted using SAS version 9.4 and as *p* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Distribution of differentially located EGFR proteins in cancer tissues {#Sec8}
----------------------------------------------------------------------

Among the 161 lung adenocarcinoma specimens, high **m**EGFR and **n**EGFR expression was observed in 69 (42.86%) and 63 (39.13%) specimens, respectively. The distribution of differentially located EGFR proteins in cancer tissues had shown 36 (22.36%) with high **m**EGFR and **n**EGFR staining, 33 (20.50%) with high **m**EGFR and low **n**EGFR staining, 27 (16.77%) with low **m**EGFR and high **n**EGFR staining, and 65 (40.37%) with low **m**EGFR and **n**EGFR staining. **m**EGFR expression significantly correlated with **n**EGFR expression (*p* = 0.0033, Additional file [1](#MOESM1){ref-type="media"}: Table S1). In addition, we found that morphologic characteristics were different in cancer tissues with high **m**EGFR expression, high **n**EGFR expression and EGFR mutations. The case numbers in certain subtypes of pathology were too small to draw definite conclusion. The detailed data was shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2.

Clinical significance of different localizations of EGFR protein {#Sec9}
----------------------------------------------------------------

A significantly high number of patients with low nodal stage had high **m**EGFR expression (odds ratio\[OR, 95% CI\] = 2.01\[1.06--3.81\], *p* = 0.031; adjusted OR\[95% CI\] = 3.92\[1.25\~ 12.27\], *p* = 0.019, respectively, Table [1](#Tab1){ref-type="table"}). Compared with those with low **m**EGFR expression, high **m**EGFR expression was significantly associated with low recurrence risk in patients without brain metastasis (in univariate analyses, HR\[95% CI\] = 0.63\[0.40--0.99\], *p* = 0.045; in multivariate analyses, HR\[95% CI\] = 0.56 \[0.34\~ 0.91\], *p* = 0.018 in PFS) and was significantly associated with reduced mortality risk in older patients (\> 70 years), those with a history of smoking, and those without brain metastasis (in univariate analyses, HR\[95% CI\] = 0.59\[0.36--0.97\], 0.54\[0.30--0.99\] and 0.56\[0.34--0.91\] in OS, respectively; in multivariate analyses, 0.55\[0.32\~ 0.92\], 0.51\[0.26\~ 0.98\] and 0.56\[0.33\~ 0.94\] in OS, respectively). High **n**EGFR expression was significantly associated with recurrence risk (in univariate analyses, HR\[95% CI\] = 1.58\[1.01--2.45\] in PFS and in multivariate analyses, HR\[95% CI\] = 1.68\[1.05\~ 2.68\] in PFS, respectively), but did not affect mortality risk (*p* = 0.677). Notably, patients with a history of smoking who had high **n**EGFR expression had a significantly lower mortality risk than those who had low **n**EGFR expression (in univariate analyses, HR\[95% CI\] = 0.55\[0.30--0.99\] in OS and in multivariate analyses, HR\[95% CI\] = 0.49\[0.25\~ 0.97\] in OS, respectively). All data are presented in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. However, EGFR expressions (**m**EGFR and **n**EGFR) were not affected by EGFR mutations (*p* = 0.205 and *p* = 0.734, Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of high membranous and nuclear EGFR expression in lung adenocarcinomaCharacteristicsNoHigh membranous EGFR (*N* = 69)OR (95% CI)*P* valueHigh nuclear EGFR (*N* = 63)OR (95% CI)*P* valueAge (median = 71 yr)0.4230.966 Younger7730 (39.0)^a^130 (38.9)1 Older \> 70 yr8439 (46.4)1.36 (0.73\~ 2.54)33 (39.3)1.01 (0.54\~ 1.91)Gender0.4360.692 Female9041 (45.6)134 (37.8)1 Male7128 (39.5)0.78 (0.41\~ 1.46)29 (40.8)1.14 (0.60\~ 1.46)Smoking0.7760.919 Never10358 (56.3)140 (38.8)1 Current or past5834 (58.6)0.91 (0.47\~ 1.75)23 (39.7)1.04 (0.54\~ 1.20)Tumor stage (2 missing)0.5840.455 T1/T28033 (41,3)134 (42.5)1 T3/T47936 (45.6)1.19 (0.64\~ 2.23)29 (36.7)0.78 (0.42\~ 1.48)Nodal stage (1 missing)**0.031**0.466 L0/L16836 (52.9)2.01 (1.06\~ 3.81)^b^29 (42.6)1.27 (0.67\~ 2.41) L2/L39233 (35.9)134 (36.9)1Metastasis0.0900.118 without6734 (50.7)131 (46.3)1 with9435 (37.2)0.58 (0.30\~ 1.09)32 (34.0)0.60 (0.32\~ 1.14)TNM stage**0.045**0.247 Localized (stage I/II)4324 (55.8)2.05 (1.01\~ 4.16)^c^20 (46.5)1.52 (0.75\~ 3.08) Distant (stage III/IV)11845 (38.1)143 (36.4)1Brain metastasis0.5150.890 without11447 (41.2)145 (39.5)1 with4722 (46.8)1.25 (0.63\~ 2.49)18 (38.3)0.95 (0.47\~ 1.91)EGFR mutations^d^0.2050.634 Wildtype7428 (37.8)127 (36.5)1 Mutations^e^7737 (48.0)1.52 (0.79\~ 2.91)31 (40.3)1.17 (0.61\~ 2.26)Chi-squared test^a^Data are presented as n (%) of row^b^Adjusted OR (95% CI) = 3.92 (1.25\~ 12.27), *p* = 0.019^c^Adjusted OR (95% CI) = 1.37 (0.32\~ 5.98) *p* = 0.674^d^10 missing^e^Including 3 in exon 18, 37 in exon 19, 3 in exon 20, 33 in exon 21and 1 in exon 19/20Note: Boldfaces as statistical significanceTable 2Univariate analyses for progression-free and overall survival in lung adenocarcinomaVariableHigh membranous EGFRHigh nuclear EGFRParameterNoPFSOSPFSOS^a^HR (95%CI)*p*^a^HR (95%CI)*p*^b^HR (95%CI)*p*^b^HR (95%CI)*p*All patients1610.79 (0.56\~ 1.13)0.1980.71 (0.49\~ 1.03)0.0671.03 (0.73\~ 1.46)0.8650.81 (0.56\~ 1.17)0.251Older age (\>  70 yr)840.64 (0.39\~ 1.04)0.0680.59 (0.36\~ 0.97)**0.038**0.81 (0.50\~ 1.31)0.3940.69 (0.40\~ 1.10)0.101Smokers580.62 (0.35\~ 1.09)0.0920.54 (0.30\~ 0.99)**0.046**0.61 (0.34\~ 1.10)0.1020.55 (0.30\~ 0.99)**0.043**Distant (metastasis)941.01 (0.66\~ 1.56)0.9540.83 (0.54\~ 1.29)0.4031.58 (1.01\~ 2.45)**0.043**1.10 (0.70\~ 1.73)0.677No brain metastasis1140.63 (0.40\~ 0.99)**0.045**0.56 (0.34\~ 0.91)**0.019**1.01 (0.66\~ 1.56)0.9530.78 (0.49\~ 1.25)0.297Wildtype EGFR740.60 (0.35\~ 1.03)0.0590.64 (0.37\~ 1.09)0.0940.84 (0.50\~ 1.41)0.5060.74 (0.43\~ 1.26)0.265Cox proportional hazards model^a^Low membranous EGFR expression as a reference^b^Low nuclear EGFR expression as a referenceNote: Boldfaces as statistical significanceTable 3Multivariate analyses for progression-free and overall survival in lung adenocarcinomaVariableHigh membranous EGFRHigh nuclear EGFRParameterNoPFSOSPFSOS^a^HR (95%CI)*p*^a^HR (95%CI)*p*^b^HR (95%CI)*p*^b^HR (95%CI)*p*All patients1610.72 (0.50\~ 1.04)0.0780.70 (0.47\~ 1.03)0.0710.89 (0.61\~ 1.29)0.5290.72 (0.49\~ 1.07)0.103Older age (\>  70 yr)840.60 (0.36\~ 0.99)0.0460.55 (0.32\~ 0.92)**0.023**0.77 (0.47\~ 1.27)0.3100.62 (0.37\~ 1.05)0.077Smokers580.63 (0.34\~ 1.16)0.1350.51 (0.26\~ 0.98)**0.045**0.64 (0.34\~ 1.21)0.1660.49 (0.25\~ 0.97)**0.041**Distant (metastasis)941.20 (0.76\~ 1.88)0.4341.00 (0.63\~ 1.61)0.9851.68 (1.05\~ 2.68)**0.030**1.27 (0.77\~ 2.08)0.350No brain metastasis1140.56 (0.34\~ 0.91)**0.018**0.56 (0.33\~ 0.94)**0.028**0.86 (0.54\~ 1.36)0.5210.72 (0.44\~ 1.18)0.186Wildtype EGFR740.49 (0.28\~ 0.85)**0.012**0.51 (0.29\~ 0.90)**0.019**0.73 (0.43\~ 1.24)0.2400.62 (0.36\~ 1.08)0.092Cox proportional hazards model after adjustment of other variables except distant^a^Low membranous EGFR expression as a reference^b^Low nuclear EGFR expression as a referenceNote: Boldfaces as statistical significance

Survival benefits of the combination of differentially located EGFR proteins {#Sec10}
----------------------------------------------------------------------------

Since **n**EGFR proteins originate from the nuclear translocation of **m**EGFR proteins, we combined both immunostain types and divided them into four subgroups (**m**EGFR^−^ **n**EGFR^−^, **m**EGFR^+^ **n**EGFR^−^, **m**EGFR^−^ **n**EGFR^+^, and **m**EGFR^+^ **n**EGFR^+^), to investigate the synergistic effects on survival outcome. Although we did not find any survival differences among all patients (*p* = 0.112, data not shown), patients with low **m**EGFR and **n**EGFR expression had the lowest survival rate among patients without brain metastasis and with a history of smoking (*p* = 0.018 and 0.062, respectively, Fig. [2a and b](#Fig2){ref-type="fig"}).Fig. 2Survival analyses. **a** patients without brain metastasis and **b** patients with a history of smoking, stratified by high **m**EGFR and **n**EGFR expression; **c** total patients stratified by **t**EGFR expression and EGFR mutations

Next, we considered high **m**EGFR and **n**EGFR expression together as total EGFR (**t**EGFR) expression, defined as either high **m**EGFR or **n**EGFR expression, to investigate the treatment response in patients receiving different anti-cancer therapies. **t**EGFR expression was significantly associated with a reduced mortality risk in patients with a history of smoking and without brain metastasis (HR\[95% CI\] = 0.24\[0.07--0.81\], *p* = 0.013; HR\[95% CI\] = 0.43 \[0.18--1.06\], *p* = 0.045, respectively) who were receiving platinum-based chemotherapy, as well as in patients without brain metastasis (HR \[95% CI\] = 0.45\[0.20--0.98\], *p* = 0.040) after EGFR TKI use. All data are shown in Table [4](#Tab4){ref-type="table"}.Table 4Comparisons of treatment responses according to **t**EGFR expressionParametersNo**t**EGFRMedian^a^ (m)HR (95%CI)*P* valueSmokers Platinum9Positive59.80.24 (0.07\~ 0.81)**0.013**8Negative20.91 TKIs9Positive32.10.40 (0.12\~ 1.33)0.1226Negative16.21 Radiation9Positive17.00.56 (0.21\~ 1.53)0.25311Negative13.11No brain metastasis Platinum18Positive59.80.43 (0.18\~ 1.06)**0.045**14Negative23.41 TKIs20Positive33.30.45 (0.20\~ 0.98)**0.040**16Negative17.51 Radiation14Positive58.20.55 (0.20\~ 1.48)0.23011Negative12.31^a^Median = median survival timeNote: Boldfaces as statistical significance

Synergistic effect of tEGFR protein and EGFR mutations on overall survival {#Sec11}
--------------------------------------------------------------------------

Based on lung adenocarcinoma patients with EGFR mutations responsible to EGFR TKIs, we compared the combined effects of **t**EGFR protein and EGFR mutations on clinical benefits. Univariate analysis had shown the survival difference (*p* = 0.001, Fig. [2c](#Fig2){ref-type="fig"}) in four subgroups (**t**EGFR^**−**^ mutant^**−**^, **t**EGFR^+^ mutant^**−**^, **t**EGFR^**−**^ mutant^+^ and **t**EGFR^+^ mutant^+^). Then we examined the treatment response to platinum-based chemotherapy and found that comparing with patients without any biomarker (**t**EGFR^**−**^ mutant^−^), **t**EGFR protein was significantly associated with low mortality risk (HR\[95% CI\] = 0.33\[0.12\~ 0.92\], *p* = 0.029; adjusted HR\[95% CI\] = 0.36\[0.13\~ 1.02\], *p* = 0.055, with the use of TKI). All data are shown in Table [5](#Tab5){ref-type="table"}.Table 5Hazard ratios for overall survival in the joint subgroups with platinum-based chemotherapy**t**EGFR/mutantNumberMedian (m)^a^Unadjusted HR (95% CI)*p*Adjusted HR^b^ (95%CI)*p***t**EGFR^−^ mutant^−^1118.21.01.0**t**EGFR^+^ mutant^−^1034.70.33 (0.12\~ 0.92)**0.029**0.36 (0.13\~ 1.02)0.055**t**EGFR^−^ mutant^+^1029.50.65 (0.41\~ 1.04)0.0700.64 (0.39\~ 1.05)0.076**t**EGFR^+^ mutant^+^2125.90.74 (0.56\~ 0.97)**0.033**0.83 (0.59\~ 1.15)0.260Cox proportional model^a^Median (m) = median survival time (month)^b^Adjusted hazard ratio with TKINote: Boldfaces as statistical significance

Discussion {#Sec12}
==========

This study investigated differentially located EGFR expression in lung adenocarcinoma. Our data indicate that high **m**EGFR expression is a more favorable prognostic factor in older patients, those with a history of smoking, and those without brain metastasis. Moreover, high **n**EGFR expression predicts early relapse in patients with distant metastasis. Notably, the combination of **m**EGFR and **n**EGFR expression is associated with survival benefits and with a more favorable response to anti-cancer therapies in patients with a history of smoking and without brain metastasis. Therefore, we suggest that differentially located EGFR expression synergistically predict survival outcomes and treatment responses in lung adenocarcinoma patients.

In this study, a high number of patients with low nodal stage exhibited high **m**EGFR expression, possibly indicating the initial stage of lung carcinogenesis. These results are different from those obtained in previous studies, which have reported a higher prevalence of EGFR overexpression in tumors of advanced stage and with lymph node invasion in colon and pancreatic cancer as well as in early stage (IA to IIIA) NSCLC \[[@CR5], [@CR20], [@CR21]\]. Nevertheless, we did not observe any clinical associations for **n**EGFR proteins, although **n**EGFR has been associated with higher-stage breast cancer and higher disease stage in early-stage NSCLC \[[@CR14], [@CR19]\]. Such differences might have been a result of most enrolled patients having advanced-stage lung adenocarcinoma.

In accordance with recent studies on breast, ovarian and head-and-neck cancers, which have reported the prognostic value of **n**EGFR proteins for survival outcomes \[[@CR12], [@CR13], [@CR19]\], the role of **n**EGFR expression in predicting recurrence risk in the metastasis subgroup was addressed in this study. However, clinicians may provide multi-agent therapies to patients with lung cancer relapse; therefore, the survival outcomes in patients with metastasis exhibited no differences. Altogether, we suggest that adjusting clinical management according to **n**EGFR expression at initial diagnosis might reduce early recurrence risk in patients with advanced lung adenocarcinoma.

In contrast to previous studies that EGFR overexpression has been associated with poor survival prognosis \[[@CR5], [@CR6], [@CR22]\], this study has determined the survival benefits of differentially located EGFR proteins in those who had a history of smoking and no brain metastasis by observing more favorable treatment responses in patients with **t**EGFR expression. Although we could not exclude the effects of EGFR mutations on anti-EGFR therapies, we had found that patients with **t**EGFR protein was responsible to platinum-based chemotherapy regardless of EGFR mutations by observing the **t**EGFR^+^ mutant^**−**^ subgroup with significantly less mortality risk than the **t**EGFR^−^ mutant^**−**^ subgroup. Our findings are in accordance with a recent Chinese study that IHC positive **m**EGFR expression is associated with responses to EGFR TKIs in NSCLC patients with wildtype EGFR status \[[@CR23]\]. Targeting EGFR protein has been reported to be an important treatment option for NSCLC \[[@CR24]\]; therefore, EGFR proteins might be an indicator for treatment responses in patients with lung adenocarcinoma. However, the true mechanism warrants further investigation.

Conclusions {#Sec13}
===========

This present study indicated that differentially located EGFR proteins might serve as a molecular marker of survival outcomes in patients with lung adenocarcinoma. Since EGFR proteins were responsible to platinum-based chemotherapy, treatment selection according to EGFR expression might be essential in the treatment of lung adenocarcinoma patients. Prospective studies are required to validate our theory.
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===============

 {#Sec14}

Additional file 1: **Table S1.** Distribution of differentially located EGFR expression in lung adenocarcinoma and **Table S2.** Morphologic characteristics for **m**EGFR expression, **n**EGFR expression and EGFR mutations in lung adenocarcinoma. (DOCX 16 kb)
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